{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-029012","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.940988+00:00","generated_at":"2026-05-31T05:14:40.648425+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar reports positive early human data for MNPR-101-Zr tumor targeting","bullets":["MNPR-101-Zr PET image at 168h post-dose in first cancer patient shows high preferential uptake in metastatic tumors.","Uptake aligns with FDG-PET locations; imaging performed on high-sensitivity Siemens Biograph Vision Quadra scanner.","Company aims to launch MNPR-101-Lu Phase 1 therapeutic trial in Q4 2024.","Additional data to be presented at EANM 2024 Congress (Oct 19-23) as 'Top-Rated Oral Presentation'.","MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-029012","json":"https://secwatch.observer/filing/0001437749-24-029012.json","markdown":"https://secwatch.observer/filing/0001437749-24-029012.md","text":"https://secwatch.observer/filing/0001437749-24-029012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924029012/0001437749-24-029012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924029012/mnpr20240911_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:14:40.648425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}